Blood Screening Market Analysis

ID: MRFR/MED/5434-HCR

85 Pages

Rahul Gotadki

October 2025

Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Blood Screening Market Industry Landscape

The dynamics of this business are very complicated, and there is an interaction between many factors that contribute to its growth and evolution in the global economy today (Sofia et al., 2013). It is important to note that this segment of human healthcare provides crucial diagnostic data for identification as well as supervision of different health conditions worldwide (Peter et.al., 2013). Technological progress mainly drives these market dynamics (Buttaliyev & Maneshin 2015). These innovations have greatly improved accuracy and efficiency, which has helped improve diagnostics during transfusion tests like HIV/AIDS Hepatitis A&B&C tests, among others (Rapid HIV/AIDS tests, 2013). The other advances in screening technologies include the use of nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), and next-generation sequencing (NGS), among others that have improved blood-screening accuracy and efficiency. Such developments will ensure that more infectious diseases like syphilis, hepatitis, and HIV can be identified. They can also help identify genetic markers of some diseases. Government actions plus regulations are one of the main factors shaping this market. Through enforcement, globally implemented strict regulatory frameworks and mandatory screening programs on health guarantee the safety of blood transfusion as well as organ transplantations. Compliance with regulations set by the government is the priority for operators in this area, which makes them invest in R&D to satisfy the current requirements of these regulators. The blood screening industry has also been boosted by increasing global awareness about avoidance care policies. For instance, periodic checks for conditions like diabetes mellitus, cholesterol levels, and cancerous tumors have become an integral part of wellness checkups. This kind of attitude towards preventive care increases the importance attached to early disease detection, thus driving the demand for blood-screening services. The blood screening market is also influenced by economic factors such as healthcare spending and insurance coverage. The expansion of screening services is boosted by increasing healthcare spending, particularly in emerging economies. Market competition is a significant determinant of the blood screening landscape. The sector experiences fierce competition because many firms provide their products for screening purposes. They spend money on research and development, strategic partnerships, and mergers so that they can remain competitive in this environment. The COVID-19 pandemic has permanently changed blood screening market dynamics. This has led to increased healthcare preparedness focus and emphasis on a strong diagnostic infrastructure, which has accelerated developments in diagnostics technologies. Besides, the pandemic has underlined the need for rapid, accurate blood screening capacities to deal with new infectious diseases effectively.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market valuation of the Blood Screening Market by 2035?

The Blood Screening Market is projected to reach approximately 9.898 USD Billion by 2035.

What was the market valuation of the Blood Screening Market in 2024?

In 2024, the Blood Screening Market was valued at 3.4 USD Billion.

What is the expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035?

The expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035 is 10.2%.

Which technology segment is anticipated to show significant growth in the Blood Screening Market?

The Nucleic Acid Amplification Test segment is expected to grow from 1.2 USD Billion in 2024 to 3.5 USD Billion by 2035.

What are the key products and services driving the Blood Screening Market?

Reagents and instruments are key products, with reagents projected to grow from 1.5 USD Billion in 2024 to 4.5 USD Billion by 2035.

Which end-user segment is likely to dominate the Blood Screening Market?

Hospitals are likely to dominate the end-user segment, growing from 1.7 USD Billion in 2024 to 4.8 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Blood Screening Market Size was estimated at 3.4 USD Billion in 2024. The Blood Screening industry is projected to grow from 3.747 USD Billion in 2025 to 9.898 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.2 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Blood Screening Market is poised for substantial growth driven by technological advancements and increasing health awareness.

Technological advancements in blood screening are enhancing diagnostic accuracy and efficiency, particularly in North America.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and infrastructure improvements.
Nucleic Acid Amplification Tests dominate the market, while Next-Generation Sequencing is rapidly gaining traction as a preferred method.
Key market drivers include the increasing prevalence of infectious diseases and rising awareness of blood donation and screening initiatives.

Blood Screening Market

CAGR

10.2%

Market Size & Forecast

2024 Market Size	3.4 (USD Billion)
2035 Market Size	9.898 (USD Billion)
CAGR (2025 - 2035)	10.2%
Largest Regional Market Share in 2024	North America

Major Players

Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US)

Market Trends

The Blood Screening Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing emphasis on preventive healthcare. The integration of innovative diagnostic tools and methodologies is reshaping the landscape, allowing for more accurate and efficient detection of blood-borne pathogens and diseases. This evolution is further propelled by rising awareness among healthcare providers and patients regarding the importance of early diagnosis and treatment. As a result, the market is witnessing a surge in demand for comprehensive blood screening solutions that can cater to diverse healthcare settings, from hospitals to outpatient clinics. Moreover, regulatory frameworks are evolving to support the adoption of new technologies in blood screening. Governments and health organizations are prioritizing the establishment of stringent guidelines to ensure the safety and efficacy of blood screening processes. This regulatory support, coupled with ongoing research and development efforts, is likely to enhance the overall quality of blood screening services. The Blood Screening Market appears poised for sustained growth, as stakeholders continue to invest in innovative solutions that address the complexities of modern healthcare needs. The future landscape may be characterized by a greater emphasis on personalized medicine and tailored screening protocols, reflecting the dynamic nature of this vital sector.

Technological Advancements

The Blood Screening Market is witnessing rapid technological innovations that enhance diagnostic accuracy and efficiency. Emerging tools, such as next-generation sequencing and automated analyzers, are streamlining processes and reducing turnaround times. These advancements not only improve patient outcomes but also facilitate the detection of a broader range of pathogens.

Regulatory Support

Regulatory bodies are increasingly focusing on establishing robust frameworks to ensure the safety and effectiveness of blood screening practices. This support is crucial for fostering innovation and encouraging the adoption of new technologies. Enhanced regulations may lead to improved standards in testing and quality assurance.

Growing Preventive Healthcare

There is a noticeable shift towards preventive healthcare, with more emphasis on early detection and management of diseases. This trend is driving demand for comprehensive blood screening services, as healthcare providers recognize the importance of proactive measures in improving patient health outcomes.

Blood Screening Market Market Drivers

Regulatory Framework Enhancements

The Blood Screening Market is significantly influenced by the evolving regulatory landscape. Governments and health authorities are increasingly implementing stringent regulations to ensure the safety and efficacy of blood screening processes. These regulations often mandate comprehensive testing protocols for blood products, thereby driving the demand for advanced screening technologies. For instance, the introduction of new guidelines for blood safety has led to an uptick in the adoption of automated screening systems. This regulatory push is expected to propel the Blood Screening Market forward, as compliance with these standards necessitates investment in innovative screening solutions.

Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in developing regions, serves as a vital driver for the Blood Screening Market. As countries invest in improving their healthcare systems, the establishment of new hospitals and diagnostic centers increases the demand for blood screening services. This growth is particularly evident in regions where access to healthcare has historically been limited. The World Health Organization has reported a significant increase in healthcare spending in these areas, which is likely to enhance the availability of blood screening technologies. Consequently, the Blood Screening Market is expected to benefit from this infrastructural development, as more facilities seek to implement comprehensive blood screening programs.

Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases is a crucial driver for the Blood Screening Market. As the world witnesses a surge in conditions such as hepatitis, HIV, and other blood-borne pathogens, the demand for effective blood screening solutions intensifies. According to recent estimates, the prevalence of hepatitis C alone affects millions, necessitating robust screening measures. This trend compels healthcare providers to adopt advanced blood screening technologies to ensure patient safety and effective disease management. Consequently, the Blood Screening Market is likely to experience substantial growth as healthcare systems prioritize the implementation of comprehensive screening protocols to combat these infectious threats.

Technological Innovations in Blood Screening

Technological advancements play a pivotal role in shaping the Blood Screening Market. Innovations such as nucleic acid testing (NAT) and next-generation sequencing (NGS) have revolutionized the accuracy and efficiency of blood screening processes. These technologies enable the detection of pathogens at lower levels, enhancing the safety of blood transfusions. The market for blood screening technologies is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 8% in the coming years. As healthcare providers increasingly adopt these cutting-edge solutions, the Blood Screening Market is poised for transformative growth, driven by the need for precision and reliability in screening practices.

Rising Awareness of Blood Donation and Screening

The growing awareness surrounding the importance of blood donation and screening is a significant driver for the Blood Screening Market. Educational campaigns and initiatives by health organizations have led to increased public participation in blood donation drives. This heightened awareness not only encourages more individuals to donate blood but also emphasizes the necessity of thorough screening to ensure the safety of the blood supply. As a result, the demand for blood screening services is expected to rise, with projections indicating a potential increase in screening volumes by 15% over the next few years. This trend underscores the critical role of public health education in bolstering the Blood Screening Market.

Market Segment Insights

By Technology: Nucleic Acid Amplification Test (Largest) vs. Next-Generation Sequencing (Fastest-Growing)

The Blood Screening Market showcases diverse technologies, primarily dominated by Nucleic Acid Amplification Tests (NAAT), which account for a significant portion of the market share. NAAT's effectiveness in detecting pathogens with high sensitivity has made it a preferred choice among healthcare providers. Enzyme-Linked Immunosorbent Assay (ELISA), while important, has a smaller share in comparison, reflecting its specific application niches within blood testing. Meanwhile, Next-Generation Sequencing (NGS) is rapidly gaining traction, attracting considerable attention for its comprehensive and detailed analysis capabilities. The growth trends in this segment indicate a robust upward trajectory, fueled by technological advancements and increasing awareness of infectious diseases. NGS is regarded as the fastest-growing method due to its ability to handle multiplex assays and provide rapid, accurate results. The rising incidence of viruses and a growing emphasis on precision medicine are primary drivers propelling these technologies' acceptance and market expansion in blood screening applications.

Technology: Nucleic Acid Amplification Test (Dominant) vs. Next-Generation Sequencing (Emerging)

Nucleic Acid Amplification Tests (NAAT) represent the dominant technology in the Blood Screening Market due to their unmatched sensitivity and specificity in detecting nucleic acids from pathogens. Their widespread adoption in clinical settings underscores their reliability and efficiency, making them essential for various infectious disease diagnostics. In contrast, Next-Generation Sequencing (NGS) is emerging as a key player in the market, capitalizing on its ability to provide detailed genomic insights. With its growing capacity to perform large-scale genomic analyses at reduced costs and improved turnaround times, NGS is positioned to revolutionize the landscape of blood screening, particularly in identifying complex and rare infections, thereby complementing the established NAAT technology.

By Product & Services: Reagents (Largest) vs. Instruments (Fastest-Growing)

In the Blood Screening Market, 'Reagents' hold the largest share, dominating the landscape with their essential role in various testing procedures. They are critical for the accuracy and reliability of blood screening results, which underscores their importance in clinical settings. In contrast, 'Instruments' are emerging as a significant player, experiencing rapid growth as advancements in technology drive innovation in blood screening solutions. This segment is becoming increasingly vital in enhancing efficiency and accuracy in diagnostic laboratories. The growth trends in the Blood Screening Market are being significantly influenced by the rising prevalence of blood-borne diseases and an increase in awareness regarding early diagnosis. Additionally, technological advancements in instruments, including automation and digitalization, are propelling the expansion of this segment. As healthcare institutions seek to upgrade their capabilities, the demand for innovative blood screening instruments is expected to surge, further solidifying their position in the market for the foreseeable future.

Reagents (Dominant) vs. Instruments (Emerging)

Reagents play a dominant role in the Blood Screening Market due to their essential function in the testing process. They facilitate the detection of various pathogens and markers in blood samples, making them indispensable for accurate diagnostics. The continued reliance on reliable reagents amidst growing health concerns further reinforces their market position. On the other hand, instruments are emerging as a critical component of blood screening solutions. The increasing integration of advanced technologies, such as automated testing systems and point-of-care devices, is enhancing the operational capabilities of diagnostic facilities. This influx of innovative instruments is not only improving turnaround times but also elevating the accuracy of results, thereby positioning them as a rapidly growing segment in the industry.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Blood Screening Market, the distribution of end users reveals that hospitals hold the largest share, driven by their comprehensive healthcare services and advanced diagnostic capabilities. Clinics, by contrast, are rapidly emerging, adopting blood screening technologies for faster diagnosis and treatment, reflecting a growing healthcare trend that prioritizes patient-centric services. The 'Others' category, which includes laboratories and research facilities, plays a supportive role but lacks the prominence of the primary segments.

End Users: Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals dominate the Blood Screening Market as they are equipped with sophisticated diagnostic tools and are often the primary settings for extensive blood testing. Their established infrastructure facilitates the integration of advanced screening techniques. Conversely, clinics are emerging as significant players, driven by increased patient footfall and the need for quicker, more accessible testing solutions. These smaller, more agile facilities are adapting rapidly to technological advancements, making them appealing alternatives for routine screenings. The increase in preventive healthcare initiatives further strengthens the position of clinics in this dynamic market.

Get more detailed insights about Blood Screening Market Research Report - Forecast till 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for blood screening, holding approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of blood-borne diseases, and stringent regulatory frameworks. The demand for rapid and accurate diagnostic tests is also on the rise, fueled by technological advancements and a growing focus on preventive healthcare. The United States is the leading country in this market, followed by Canada. Major players like Abbott Laboratories, Thermo Fisher Scientific, and Becton Dickinson are headquartered here, contributing to a competitive landscape. The presence of these key players ensures continuous innovation and development of new screening technologies, enhancing market growth and improving patient outcomes.

Europe : Regulatory Frameworks Drive Growth

Europe is the second-largest market for blood screening, accounting for about 30% of the global market share. The region benefits from robust healthcare systems and increasing investments in diagnostic technologies. Regulatory bodies are actively promoting blood safety and screening standards, which further drives market growth. The rising incidence of infectious diseases and the need for early diagnosis are also significant demand drivers in this region. Germany and the UK are the leading countries in the European blood screening market, with a strong presence of key players like Roche Diagnostics and Siemens Healthineers. The competitive landscape is characterized by collaborations and partnerships among companies to enhance product offerings. The focus on research and development is also prominent, ensuring that Europe remains at the forefront of blood screening innovations.

Asia-Pacific : Rapid Growth and Expansion

Asia-Pacific is witnessing rapid growth in the blood screening market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of blood-related diseases, and a growing population. Governments are investing in healthcare infrastructure and promoting initiatives for early disease detection, which are significant catalysts for market growth. China and India are the leading countries in this region, with a burgeoning demand for advanced diagnostic solutions. The competitive landscape is evolving, with both local and international players like Grifols and Bio-Rad Laboratories expanding their presence. The focus on affordable and accessible healthcare solutions is shaping the market dynamics, making Asia-Pacific a key player in the global blood screening landscape.

Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region is gradually emerging in the blood screening market, holding about 5% of the global share. The growth is primarily driven by increasing investments in healthcare infrastructure and rising awareness of blood safety. Governments are implementing policies to enhance healthcare access, which is expected to boost demand for blood screening technologies in the coming years. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities adopting advanced diagnostic solutions. The competitive landscape is characterized by a mix of local and international players, focusing on tailored solutions to meet regional needs. The presence of key players is gradually increasing, paving the way for future growth in this untapped market.

Key Players and Competitive Insights

The Blood Screening Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of blood-related diseases, and a growing emphasis on early diagnosis. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its diagnostic capabilities through continuous product development, while Roche Diagnostics (CH) emphasizes partnerships to bolster its research and development efforts. Siemens Healthineers (DE) is investing in digital transformation initiatives, which collectively shape a competitive environment that prioritizes technological superiority and strategic collaborations.

Key business tactics within the Blood Screening Market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting substantial influence. This structure allows for a competitive interplay where innovation and strategic partnerships are pivotal in maintaining market share and driving growth.

In August 2025, Abbott Laboratories (US) announced the launch of a new blood screening platform designed to improve the accuracy and speed of infectious disease detection. This strategic move is likely to enhance Abbott's competitive edge by addressing the increasing demand for rapid diagnostics, thereby positioning the company favorably in a market that values efficiency and reliability.

In September 2025, Roche Diagnostics (CH) entered into a collaboration with a leading biotechnology firm to develop next-generation blood screening assays. This partnership is indicative of Roche's commitment to innovation and suggests a strategic focus on expanding its product portfolio to meet evolving market needs. Such collaborations may enhance Roche's capabilities in delivering cutting-edge diagnostic solutions, further solidifying its market position.

In July 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics tool aimed at optimizing blood screening processes. This initiative reflects Siemens' strategic emphasis on integrating artificial intelligence into its offerings, potentially revolutionizing how blood screening is conducted. The introduction of AI technologies may not only improve operational efficiencies but also enhance diagnostic accuracy, thereby attracting a broader customer base.

As of October 2025, the Blood Screening Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the market.

Key Companies in the Blood Screening Market market include

Industry Developments

June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

Future Outlook

Blood Screening Market Future Outlook

The Blood Screening Market is projected to grow at a 10.2% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising health awareness.

New opportunities lie in:

Development of AI-driven diagnostic tools for enhanced accuracy.
Expansion of mobile blood screening units in underserved regions.
Partnerships with telehealth platforms for remote screening services.

By 2035, the Blood Screening Market is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

Blood Screening Market End User Outlook

Hospitals
Clinics
Others

Blood Screening Market Technology Outlook

Nucleic Acid Amplification Test
Enzyme-Linked Immunosorbent Assay
Next-Generation Sequencing

Blood Screening Market Product & Services Outlook

Reagents
Instruments

Report Scope

MARKET SIZE 2024	3.4(USD Billion)
MARKET SIZE 2025	3.747(USD Billion)
MARKET SIZE 2035	9.898(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	10.2% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Integration of advanced technologies enhances accuracy and efficiency in the Blood Screening Market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the blood screening market.
Countries Covered	North America, Europe, APAC, South America, MEA